Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Levormeloxifene
Другие языки:

    Levormeloxifene

    Подписчиков: 0, рейтинг: 0
    Levormeloxifene
    Levormeloxifene.svg
    Clinical data
    Other names Levomeloxifene; 6720-CDRI; NNC-460020
    Identifiers
    • 1-(2-[4-[(3R,4R)-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy]ethyl)pyrrolidine
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C30H35NO3
    Molar mass 457.614 g·mol−1
    3D model (JSmol)
    • O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5
    • InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 checkY
    • Key:XZEUAXYWNKYKPL-WDYNHAJCSA-N checkY
     ☒NcheckY (what is this?)  (verify)

    Levormeloxifene (INN; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed. The development was stopped because of a high incidence of gynecological side effects during clinical trials. Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.

    See also

    External links



    Новое сообщение